Chemoradiotherapy for locally advanced rectal cancer

doi:10.3760/cma.j.issn.1673-422X.2015.07.019

Abstract

Abstract: Surgical resection is the primary treatment for locally advanced rectal cancer, but the local recurrence rate of surgical resection is still at a high level. Preoperative and postoperative chemoradiotherapy not only decreases the local recurrence rate of surgical resection, but also elevates the survival rate and life quality. Recently, adjuvant chemoradiotherapy has been applied as the standard therapy for locally advanced rectal cancer. The application of targeted drugs, new chemotherapy drugs and rapid changing radiotherapy technology provide more approaches to the treatment of locally advanced rectal cancer.

Key words: Rectal neoplasms, Radiotherapy, Chemotherapy, adjuvant

Long Cheng, Li Guoquan, Jiang Yongmei, Yi Tienan, Sun Qiushi. Chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2015, 42(7): 545-547.

References

［1］ Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRCCR07 and NCICCTGCO16 randomized clinical trial［J］. Lancet, 2009, 373(9666): 821-828. ［2］ Greto D, Paiar F, Saieva C, et al. Neoadjuvant oxaliplatin and 5fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a singleinstitution experience［J］. Radiol Med, 2013, 118(4): 570-582. ［3］ Fitzgerald TL, Biswas T, O′Brien K, et al. Neoadjuvant radiotherapy for rectal cancer: adherence to evidencebased guidelines in clinical practice［J］. World J Surg, 2013, 37(3): 639-645. ［4］ Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials［J］. Lancet, 2001, 358 (9290): 1291-304. ［5］ Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for highrisk rectal carcinoma［J］. N Engl J Med, 1991, 324(11): 709-715. ［6］冯瑞, 李明焕, 于金明. 158例Ⅱ和Ⅲ期直肠癌根治术后不同治疗方法疗效分析［J］. 中华放射肿瘤学杂志, 2009, 18(3): 224-225. ［7］ Tulchinsky H, Shmueli E, Figer A, et al. An interval>7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and diseasefree survival in patients with locally advanced rectal cancer［J］. Ann Surg Oncol, 2008, 15(10): 2661-2667. ［8］ Lim SB, Choih S, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers［J］. Ann Surg, 2008, 248 (2): 243-251. ［9］ Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensitymodulated radiotherapy for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82 (5): 1981-1987. ［10］ Jabbour SK, Patel S, Herman JM, et al. Intensitymodulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits［J］. Int J Surg Oncol, 2012, 82(5): 1-7. ［11］ Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, noninferiority, phase 3 trial［J］. Lancet Oncol, 2012, 13(6): 579-588. ［12］ Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR01 randomized phase Ⅲ trial［J］. J Clin Oncol, 2011, 29(20): 2773-2780. ［13］ Gérard JP, Azria D, GourgouBourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial ACCORD 12/0405Prodige 2［J］. J Clin Oncol, 2010, 28(10): 1638-1644. ［14］ Gérard JP, Azria D, GourgouBourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer［J］. J Clin Oncol, 2012, 30(36): 4558-4565. ［15］ Rdel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locallyadvanced rectal cancer: initial results of the German CAO/ARO/AIO04 randomised phase 3 trial［J］. Lancet Oncol, 2012, 13(7): 679-687. ［16］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4): 1171-1178. ［17］ Gollins S, Sun Myint A, Haylock B, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imagingdefined locally advanced rectal cancer: impact on longterm clinical outcomes［J］. J Clin Oncol, 2011, 29(8): 1042-1049. ［18］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1032-1038. ［19］ Kim SY, Shim EK, Yeo HY, et al. Kras mutation statusand clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase Ⅱ trials［J］. Int J Radiat Oncol Biol Phys, 2013, 85(1): 201-207. ［20］ Dewdney A, Cunningham D, Taberbero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer(EXPERTC)［J］. J Clin Oncol, 2012, 30(14): 1620-1627. ［21］ Willett CG, Duda DG, Ancukiewicz M, et al. Asafety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase Ⅰ/Ⅱ study compared with standard chemoradiation in locally advanced rectal cancer［J］. Oncologist, 2010, 15(8): 845-851. ［22］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imaging defined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5): 614-620. ［23］ Dipetrillo T, Pricolo V, Lagaresgarcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5fluorouracil, and radiation for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(1): 124-129.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[11]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[14]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[15]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.